Head and Neck Squamous Cell Carcinoma
Conditions
Keywords
HNSCC
Brief summary
This study is a single center, single arm clinical trial for newly diagnosed patients with locally advanced head and neck squamous cell carcinoma. The main purpose is to evaluate the efficacy and safety of flutamide combined with standard immunotherapy for advanced / recurrent head and neck squamous cell carcinoma. In our previous study, we found that AR can affect the occurrence and development of tumors by regulating the differentiation of cd8+t cells. We used three different castration drugs (flutamide, goserelin and abiraterone) in animal models to treat primary and tumor bearing head and neck squamous cell carcinoma mice respectively, and found that castration treatment could significantly inhibit the tumor growth of head and neck squamous cell carcinoma. In addition, in animal models, we compared the efficacy of the combination of castration therapy and low-dose cisplatin with that of the existing first-line chemotherapy drug cisplatin, and found that the combination of castration therapy and low-dose cisplatin can significantly improve the treatment effect of head and neck squamous cell carcinoma and reduce the adverse reactions brought by the drug. Therefore, we infer that flutamide combined with standard immunotherapy can fully inhibit the growth of HNSCC and improve the prognosis of HNSCC patients.
Interventions
DRUGPembrolizumab+Flutamide
Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
Sponsors
Zhejiang Provincial People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old, ≤ 85 years old 2. Histologically or cytologically proven squamous cell carcinoma of the head and neck; Patients diagnosed with head and neck squamous cell carcinoma with stage III and IV A without distant metastasis according to AJCC staging (8th editon), including squamous cell carcinoma of oropharyngeal (P16-), oral cavity, hypopharyngeal and larynx 3. Measurable primary lesions per RECIST 1.1 criteria 4. Treatment-naive patients without any previous disease-related therapy (except for diagnostic biopsies on primary lesions) 5. ECOG performance status of 0 or 1 6. Unresectable primary, recurrent, and / or metastatic HNSCC 7. No active autoimmune disease 8. No concurrent malignancy 9. Life expectancy is estimated to be over 3 months 10. Have sufficient tumour tissue samples available for CPS PD-L1 immunohistochemical examination (22C3 DAKO) 11. No abvious signs of hematological disorders, ANC≥1.5×109 /L, platelets ≥100×109 /L, Hb≥ 90 g/L,WBC ≥3.0×109 /L before enrollment, no blood transfusion and bleeding tendency within 7 days 12. ALT,AST and ALP ≤ 2.5 × upper limit of normal (ULN); Serum bilirubin ≤ 1.5 × ULN, for patients with known Gilbert disease, serum bilirubin ≤ 3 x ULN 13. Serum creatinine ≤1.5 or creatinine clearance\>50 mL/min 14. HPV status determined by p16 IHC, in situ hybridization, or by polymerase chain reaction-based assays 15. Able to understand this study, patient and (or) legal representative voluntarily agree to participate in this trial and sign informed consent
Exclusion criteria
1. Patients who are suitable for local treatment and have the intention of local treatment 2. Received systemic treatment with Chinese patent drugs with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin) within 2 weeks before the first administration 3. Patients with tumor progression after previous treatment with flutamide analogues (antiandrogens) 4. Other malignant tumors occurred within 5 years or suffered from at the same time in the current period, except for cured non melanoma skin cancer or other tumors / cancers that have undergone radical treatment and have no signs of disease for at least 5 years; 5. According to the criteria of common adverse event terminology (NCI ctcaev5.0), there was peripheral neuropathy ≥ grade 2 6. With known active central nervous system metastasis (CNS) and / or cancerous meningitis 7. Subjects who did not recover from any acute effects of previous surgery, chemotherapy or radiotherapy, i.e. did not fall to grade ≤ 1 (NCI ctcaev5.0) (excluding hair loss). Chronic late toxicity from previous radiotherapy and / or surgery is allowed if nutritional status is stable 8. Any component of the study drug or preparation has led to severe allergic reactions, including known severe allergic reactions to flutamide and (NCI ctcaev5.0 ≥ grade 3) 9. Have received anti-tumor drug treatment (such as chemotherapy, hormone therapy, immunotherapy, antibody therapy, radiotherapy, etc.) within 4 weeks or 4 weeks before the first administration, except for palliative radiotherapy for bone to reduce pain 10. Major surgery within 4 weeks before the first dose or expected during this study 11. Immunosuppressive drugs were required 2 weeks or within 2 weeks before the first dose or during the study 12. Subjects who are known to have active, or have a history of autoimmune disease that may recur 13. Subjects with known history of interstitial lung disease, non infectious pneumonia, or high suspicion of interstitial lung disease 14. Hepatitis B or C virological examination meets any of the following requirements at the time of screening: 1. HBsAg is positive, and the titer of hepatitis B virus deoxyribonucleic acid (HBV DNA) in peripheral blood is ≥ 104 copies /ml or ≥ 2000 iu/ml; 2. HCV antibody was positive, and HCV-RNA was higher than the detection limit of the analytical method; 15. Within 2 weeks or 2 weeks before the first administration, the subject had active infection or uncontrollable infection requiring systemic treatment (except simple urinary tract infection or upper respiratory tract infection) 16. Serous cavity effusion with clinical symptoms requiring clinical intervention or stabilization time less than 4 weeks 17. Diabetes mellitus (fasting blood glucose ≥ 10mmol/l) or hypertension (systolic blood pressure ≥ 160mmhg and / or diastolic blood pressure ≥ 100mmhg) with severe medical diseases, such as grade III or above cardiac dysfunction (New York Heart Association \[nyha\]), ischemic heart disease (such as myocardial infarction or angina pectoris) and other cardiovascular diseases, or a history of myocardial infarction within 3 months before the first administration, and still poorly controlled after drug treatment (fasting blood glucose ≥ 10mmol/l) or poorly controlled hypertension (systolic blood pressure ≥ 160mmhg and / or diastolic blood pressure ≥ 100mmhg) 18. Medical or psychiatric history or history of laboratory abnormalities that may interfere with the interpretation of the results 19. Subjects are currently enrolled in the study of other investigational devices or investigational drugs, or are less than or equal to 4 weeks away from the discontinuation of other investigational drugs or investigational devices 20. Subjects were known to have alcohol or drug addiction 21. Subjects have other conditions that may affect their compliance with the protocol and evaluation of research indicators, and are not suitable to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | Up to 4 years | The Progression-Free-Survival of Interventions group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Up to 4 years | The Objective Response Rate of Intervention group |
| DOR | Up to 4 years | The Disease Control Rate of intervention group |
| OS | Up to 4 years | The overall survival of paticipated patients |
Contacts
Primary ContactGe Minghua, Doctor
Outcome results
None listed